WHO highlights progress in accelerating access to hepatitis C diagnostics and treatment in low- and middle-income countries

WHO highlights progress in accelerating access to hepatitis C diagnostics and treatment in low- and middle-income countries
WHO / Blink Media - Martyn Aim
©
Credits
WHO highlights progress in accelerating access to hepatitis C diagnostics and treatment in low- and middle-income countries
27 January 2021
Reading time:
Many low- and middle-income countries have reduced suffering from hepatitis C, thanks to increased access to testing and treatment. Some achieved a 20-fold increase in the number of people treated with safe and effective direct-acting retroviral drugs
between 2015 and 2018, according to the
A drop in prices underpins this success
Low- and middle-income countries can now aim to achieve a price as low as US$ 60 per patient for a 12-week course of treatment with WHO-prequalified generic sofosbuvir and daclatasvir. Prices offered by suppliers of WHO-prequalified HCV rapid diagnostic

Related Keywords

Minghui Ren ,Mariangela Simao ,Meg Doherty ,Department Of Global ,Health Coverage Communicable ,Global Health Sector Strategy On Viral Hepatitis ,Health Products ,Global Health Sector Strategy ,Viral Hepatitis ,Assistant Director General Access ,மெக் டோவர்டீ ,துறை ஆஃப் உலகளாவிய ,ஆரோக்கியம் பாதுகாப்பு தொடர்பு கொள்ளக்கூடியது ,உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் ஆன் வைரஸ் ஹெபடைடிஸ் ,ஆரோக்கியம் ப்ராடக்ட்ஸ் ,உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் ,வைரஸ் ஹெபடைடிஸ் ,உதவியாளர் இயக்குனர் ஜநரல் நுழைவு ,